Please assess the completion status of the following clinical trial:

Trial Title: A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must have had a diagnosis of active JIA (polyarticular, extended oligoarticular, or enthesitis-related juvenile idiopathic arthritis \[ERA\] including JPsA).~* Participants must have had an inadequate response to at least one conventional or biologic disease-modifying antirheumatic drug (DMARD).~Exclusion Criteria:~* Participants must not have systemic JIA, with or without active systemic features.~* Participants must not have persistent oligoarticular arthritis.~* Participants must not have been previously treated with a Janus kinase (JAK) inhibitor.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Baricitinib (Type: EXPERIMENTAL): Baricitinib was administered QD (once daily) as a 4-mg oral tablet for adolescent participants (12 to \<18 years of age) and children ≥9 years of age; and 2 mg for children \<9 years of age. Participants \<6 years of age received an oral suspension. Participants ≥6 to \<12 years old had the option of receiving an oral suspension. Participants \>12 years old were supplied tablets. The oral suspension dose was administered as 4-mg, 2-mg, 1-mg, and 0.5-mg as needed.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo matched to baricitinib was administered to participants during the DBW period.

Based on this trial design, predict the completion outcome and termination type (if applicable).